New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
08:10 EDTACTActavis announces final stockholder results in Forest Laboratories acquisition
Actavis announced the final results of the elections made by stockholders of Forest Laboratories as to the form of merger consideration they would receive in connection with Actavis' acquisition of Forest. Holders of approximately 13.81% of the outstanding shares of Forest common stock elected to receive 3306 of an Actavis ordinary share and $26.04 in cash, without interest, with fractions of an Actavis ordinary share being cashed out at $219.00 per Actavis ordinary share. Holders of approximately 0.44% of the outstanding Forest shares elected to receive $86.81 in cash, without interest. Holders of approximately 72.78% of the outstanding shares of Forest common stock elected to receive $25.67 in cash plus 0.3326 of an Actavis ordinary share, with fractions of an Actavis ordinary share being cashed out at $219.00. Holders of approximately 12.97% of the outstanding Forest shares failed to make a valid election or did not deliver a valid election form prior to the deadline and will receive the Standard Election Consideration for each Actavis ordinary share, with fractions of an Actavis ordinary share being cashed out at $219.00 per Actavis ordinary share.
News For ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 22, 2015
05:57 EDTACTActavis, Valeant raise prospects of more healthcare deals, Financial Times says
Subscribe for More Information
January 21, 2015
12:30 EDTACTGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
07:22 EDTACTActavis price target raised to $330 from $280 at Deutsche Bank
Subscribe for More Information
January 20, 2015
05:34 EDTACTActavis reports positive Phase III results for cariprazine
Gedeon Richter and Actavis announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia. There were 101 patients randomized to cariprazine 3 to 9 mg per day and 99 randomized to placebo. The primary efficacy measure was time to first relapse during the double-blind period. There were 25 relapses in the cariprazine group versus 47 relapses in the placebo group. Treatment with cariprazine was associated with a 55% reduction in risk of relapse versus placebo.
January 14, 2015
18:18 EDTACTOn The Fly: After Hours Movers
Subscribe for More Information
16:59 EDTACTGalena, Orexo AB receive "Paragraph IV" patent certification notice from Actavis
Subscribe for More Information
January 13, 2015
14:00 EDTACTActavis says Allergan deal could close as early as Q1, as late as Q2
Subscribe for More Information
13:49 EDTACTActavis says sees about $8B in free cash flow in 2016
Subscribe for More Information
13:42 EDTACTActavis targeting 2017 EPS of $25
Subscribe for More Information
13:38 EDTACTActavis sees Q4 adjusted EPS beating consensus by 10%-15%
Subscribe for More Information
08:05 EDTACTActavis launches US generic specialty injectable portfolio
Actavis announced the launch of a portfolio of generic specialty injectable medications to be marketed to hospitals across the United States. Actavis will immediately begin marketing approximately 20 injectable products across a number of therapeutic categories in the U.S. The company hopes to be a leader in Oncology, with nearly a dozen marketed products including generic versions of Gemzar, Taxotere, Campostar and Zometa. Actavis also has an industry leading specialty injectable pipeline, with approximately 20 new filings under review at the U.S. Food and Drug Administration, as well as more than 50 additional projects currently in development.
January 12, 2015
12:45 EDTACTActavis CEO says 'can't speculate on what Pfizer is going to do'
Subscribe for More Information
12:10 EDTACTRBC Capital says Celgene's shares could rise to $200 'over time'
The long-term profit guidance that Celgene (CELG) released today suggests that the stock, currently trading around $115, could reach $200 "over time," RBC Capital wrote in a note to investors today. WHAT'S NEW: After Celgene estimated that its EPS would exceed $12.50, excluding certain items, by 2020, RBC Capital says that the guidance exceeded the firm's previous outlook. RBC added that Celgene's projection increases its confidence in the predictability of the drug maker's performance over the longer term. The firm recommended that investors own Celgene in 2015, noting that the company has the potential to settle its patent case with Actavis (ACT). A settlement would enable investors to focus on Celgene's visible long-term growth and the robust opportunity provided by its drugs in development, RBC stated. Historically, investors have not given Celgene credit for these strengths, the firm stated. PRICE ACTION: In early afternoon trading, Celgene rose 1.5% to $115.35.
09:37 EDTACTSupreme Court rejects Allergan appeal on generic Latisse, Bloomberg reports
08:34 EDTACTActavis expects Q4 non-GAAP EPS to exceed consensus by 10%-15%
Subscribe for More Information
08:09 EDTACTActavis and Allergan announce early termination of HSR waiting period
Subscribe for More Information
08:07 EDTACTActavis, Allergan announce early termination of Hart Scott Rodino waiting period
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use